NanoViricides Inc Stock Price and Quote (2024)

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.81	Insider Own	4.62%	Shs Outstand	11.70M	Perf Week	11.25%
Market Cap	31.53M	Forward P/E	-	EPS next Y	-0.68	Insider Trans	0.00%	Shs Float	11.27M	Perf Month	31.53%
Income	-9.51M	PEG	-	EPS next Q	-0.31	Inst Own	10.12%	Short Float	1.12%	Perf Quarter	140.54%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	19.10%	Short Ratio	0.79	Perf Half Y	128.21%
Book/sh	0.90	P/B	2.96	EPS next Y	-	ROA	-63.30%	Short Interest	0.13M	Perf Year	142.73%
Cash/sh	0.28	P/C	9.67	EPS next 5Y	-	ROE	-65.85%	52W Range	1.00 - 2.95	Perf YTD	161.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.25%	ROI	-89.27%	52W High	-9.49%	Beta	1.04
Dividend TTM	-	Quick Ratio	4.32	Sales past 5Y	0.00%	Gross Margin	-	52W Low	167.00%	ATR (14)	0.21
Dividend Ex-Date	-	Current Ratio	4.32	EPS Y/Y TTM	-38.42%	Oper. Margin	0.00%	RSI (14)	72.44	Volatility	9.90% 12.07%
Employees	7	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	6.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-7.59%	Payout	-	Rel Volume	1.14	Prev Close	2.65
Sales Surprise	-	EPS Surprise	5.26%	Sales Q/Q	-	Earnings	Feb 16 AMC	Avg Volume	159.59K	Price	2.67
SMA20	20.58%	SMA50	62.75%	SMA200	104.05%	Trades		Volume	181,956	Change	0.75%

open in yahoo|&nbspopen in reuters|&nbspopen in marketwatch|&nbspopen in google|&nbspopen in EDGAR

NanoViricides Inc Stock Price and Quote (1)

NanoViricides Inc Stock Price and Quote (2)

Date	Action	Analyst	Rating Change	Price Target Change
Feb-11-15	Initiated	Midtown Partners	Strong Buy	$5.30

NanoViricides Inc Stock Price and Quote (3)

Jun-04-24 06:30AM	The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect (ACCESSWIRE)
May-29-24 06:30AM	A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More (ACCESSWIRE) +10.45%
May-23-24 06:30AM	NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc. (ACCESSWIRE)
May-20-24 06:30AM	Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure (ACCESSWIRE)
May-15-24 06:58AM	NanoViricides: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -20.35%
06:30AM	Loading…
06:30AM	NanoViricides Has Filed its Quarterly Report (ACCESSWIRE)
May-14-24 06:30AM	A Novel Broad-Spectrum Antiviral with Activity Against RSV (ACCESSWIRE) +24.18%
May-10-24 06:30AM	NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City (ACCESSWIRE)
May-08-24 06:30AM	A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox (ACCESSWIRE) +20.83%
May-06-24 06:30AM	A Novel Broad-Spectrum Antiviral with Activity Against Influenza A (ACCESSWIRE) +23.89%
May-02-24 06:30AM	3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire (InvestorPlace) +6.19%
Apr-30-24 06:30AM	NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon (ACCESSWIRE) +6.19%
Feb-15-24 06:30AM	NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon (ACCESSWIRE)
Feb-14-24 05:11PM	NanoViricides: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
Feb-01-24 06:20AM	Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics (ACCESSWIRE)
06:30AM	Loading…
Jan-29-24 06:30AM	Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found (ACCESSWIRE) +9.35%
Jan-04-24 06:30AM	NanoViricides to Present at the Biotech Showcase in San Fransisco (ACCESSWIRE) +5.83%
Nov-29-23 01:32PM	NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387 (News Direct)
Nov-28-23 06:40AM	The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Companys Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides (ACCESSWIRE) +13.73%
Nov-15-23 06:45AM	NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications (ACCESSWIRE) -9.70%
05:04AM	NanoViricides: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
Nov-14-23 06:45AM	Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development (ACCESSWIRE) +11.67%
Oct-16-23 06:45AM	NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV (ACCESSWIRE)
Oct-12-23 06:45AM	NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET (ACCESSWIRE)
Sep-27-23 08:45AM	Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant (News Direct)
Sep-05-23 06:49AM	NNVC: NanoViricides Begins Clinical Trial of NV-CoV-2 (Zacks)
Aug-31-23 08:00AM	NanoViricides progressing well with new Covid study (News Direct)
Aug-21-23 06:45AM	The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Companys Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides (ACCESSWIRE) +7.75%
Jul-19-23 09:15AM	SARS-CoV-2 Is Not Done Yet Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19? (News Direct)
Jul-13-23 08:31AM	NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst (News Direct) -8.81%
09:25AM	Loading…
Jul-11-23 09:25AM	Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials What Other Viruses Could This COVID Treatment Target? (News Direct) +10.64%
06:45AM	Companys Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides (ACCESSWIRE)
Jul-06-23 09:00AM	NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment (News Direct)
06:45AM	Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs (ACCESSWIRE)
Jun-29-23 03:00PM	NanoViricides take big step forward beginning trials on its antiviral drug NV-CoV-2 (News Direct)
06:45AM	NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun (ACCESSWIRE)
Jun-07-23 08:56PM	The 7 Most Promising Penny Stocks to Buy in June (InvestorPlace)
May-31-23 06:40AM	NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET (ACCESSWIRE)
May-16-23 06:54AM	NanoViricides: Fiscal Q3 Earnings Snapshot (AP Finance) -5.36%
06:45AM	NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin (ACCESSWIRE)
May-04-23 06:45AM	NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City (GlobeNewswire)
Apr-25-23 06:45AM	NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient (ACCESSWIRE)
Apr-17-23 06:45AM	NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate (ACCESSWIRE) +21.64%
Apr-12-23 01:59PM	NanoViricides using unique technology platform to fight against viruses (News Direct)
Apr-10-23 08:01AM	NNVC: NanoViricides Technology Ready to Enter the Clinic (Zacks Small Cap Research) -9.70%
Apr-04-23 07:45AM	NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates (ACCESSWIRE) +23.85%
Mar-31-23 11:15AM	COVID Remains A Global Threat NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All (News Direct)
Mar-20-23 09:45AM	A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats (News Direct)
Mar-08-23 10:45AM	With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It (News Direct)
Feb-15-23 06:30AM	NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials (ACCESSWIRE)
Jan-04-23 06:35AM	NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT (ACCESSWIRE) +11.50%
Dec-05-22 06:45AM	NanoViricides, Inc. to Present at the RHK Capital Disruptive Growth Conference in New York City on December 6th at 1:20pm ET (ACCESSWIRE)
Nov-15-22 06:45AM	NanoViricides, Inc. Has Filed its Quarterly Report: Coronavirus Drug NV-CoV-2 IND Stage (ACCESSWIRE)
Oct-28-22 02:49PM	7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov. (InvestorPlace)
Oct-27-22 09:25AM	This Company Is Looking For A Monkeypox Drug As City Investigates Deaths (News Direct)
Oct-14-22 06:40AM	NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug NV-CoV-2 IND Stage (ACCESSWIRE)
Sep-19-22 09:26AM	NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly (News Direct) -7.73%
Aug-10-22 08:00AM	Monkeypox Is Popping Up In Places It Shouldnt But NanoViricides SaysIt May Have A Solution (News Direct)
Aug-09-22 06:45AM	NanoViricides Provides Additional Details on Its Rapid Monkeypox Drug Strategy (ACCESSWIRE) -9.71%
Aug-04-22 09:01AM	NanoViricides shares soar 41% after announcing plans to develop a monkeypox treatment (MarketWatch) +48.37%
06:45AM	NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus (ACCESSWIRE)
May-17-22 06:45AM	NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application (ACCESSWIRE)
May-16-22 12:22PM	NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis (Benzinga) +12.19%
06:45AM	NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis (ACCESSWIRE)
Apr-25-22 06:45AM	NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program (ACCESSWIRE)
Feb-15-22 06:45AM	NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready (ACCESSWIRE)
Nov-16-21 06:45AM	NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials (ACCESSWIRE)
Nov-15-21 07:31AM	EXCLUSIVE: NanoViricides Completes Oral Gummies, Lung Inhalation Formulations For COVID-19 Treatment (Benzinga)
06:45AM	NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2 (ACCESSWIRE)
06:18AM	EXCLUSIVE: NanoViricides Develops Chewable Pills, Lung Inhalation Formulations For COVID-19 Candidate (Benzinga)
Oct-13-21 06:45AM	NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage (ACCESSWIRE) +14.69%
Oct-11-21 08:25AM	NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity (Benzinga)
Oct-05-21 08:31AM	NanoViricides Leaps Forward in its Quest to Defeat COVID-19 (Benzinga) +5.64%
06:45AM	NanoViricides Provides Update on Its Pan-Coronavirus COVID-19 Drug Development Program at Benzinga Healthcare Small Cap Conference (PR Newswire)
Sep-28-21 09:28AM	Company News for Sep 28, 2021 (Zacks)
Sep-27-21 07:02AM	20 Stocks Moving in Monday's Pre-Market Session (Benzinga)
06:45AM	NanoViricides, Inc. Invites You to Join Us at the Benzinga Healthcare Small Cap Conference for Update on Pan-Coronavirus COVID-19 Drug Development Program (Newsfile)
Sep-22-21 06:45AM	Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug (PR Newswire) -7.11%
Sep-21-21 02:18PM	Nanoviricides Stock Surges, Nears The End Of A Pennant Pattern (Benzinga) +63.32%
Sep-14-21 12:04PM	36 Stocks Moving In Tuesday's Mid-Day Session (Benzinga) +18.67%
07:32AM	NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development (Benzinga)
Jun-28-21 08:28AM	Nanomedicine Company Makes "Nanomachines" that Attack Viruses (Benzinga)
Jun-22-21 12:49PM	NanoViricides Review: What you Need to Know About the Company (Benzinga) +7.89%
May-17-21 06:45AM	NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards IND (ACCESSWIRE)
Mar-09-21 08:08AM	The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data (Benzinga)
05:45AM	NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in Support of FDA Pre-IND Application (ACCESSWIRE)
Mar-02-21 08:01AM	The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data (Benzinga) +57.58%
06:15AM	NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application (ACCESSWIRE)
04:43AM	NanoViricides Reports 'Strong Effectiveness' for COVID Drugs (TheStreet.com)
Feb-18-21 04:59AM	We're Hopeful That NanoViricides (NYSEMKT:NNVC) Will Use Its Cash Wisely (Simply Wall St.) -7.61%
Feb-17-21 06:15AM	NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug Candidate Safe in GLP Safety Toxicology Moving Towards IND (ACCESSWIRE)
Feb-08-21 07:40AM	NanoViricides' Broad-Spectrum Antiviral Drug Candidate Shows Encouraging Action In Preclinical Studies For COVID-19 (Benzinga) +13.80%
06:15AM	NanoViricidess Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety Studies (ACCESSWIRE)
Jan-27-21 06:15AM	Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants, Says NanoViricides, Inc.s President, Dr. Anil Diwan (ACCESSWIRE)
Nov-19-20 06:20AM	NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA (ACCESSWIRE)
Nov-18-20 11:49AM	Small Caps Daily Features NanoViricides' Rapid Advancement to Clinical Trials for its COVID-19 Therapy (Newsfile)
Nov-17-20 06:20AM	NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2020 - Has Sufficient Cash, Coronavirus Drug Development Progress (ACCESSWIRE)
Nov-11-20 10:55AM	NanoViricides: One Step at a Time (GuruFocus.com)
06:20AM	NanoViricides Has Engaged Calvert Labs for Safety Pharmacology Studies of Its Drug for the Treatment of COVID-19 (ACCESSWIRE)
Oct-15-20 06:15AM	NanoViricides, Inc. Has Filed its Annual Report: Strengthened Financial Position and Rapidly Developing Novel Coronavirus Drug Program (ACCESSWIRE)

NanoViricides Inc Stock Price and Quote (4)

NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.

NanoViricides Inc Stock Price and Quote (5)

NanoViricides Inc Stock Price and Quote (6)

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions withourpremium features. Real-time quotes, advancedvisualizations, backtesting, and much more.

Learn more about FINVIZ*Elite

NanoViricides Inc Stock Price and Quote (2024)

Upgrade your FINVIZ experience

References